Oruka Therapeutics Inc’s recent filing unveils that its 10% Owner Venrock Healthcare Capital Par acquired Company’s shares for reported $1.02 million on Feb 14 ’25. In the deal valued at $11.44 per share,88,794 shares were bought. As a result of this transaction, Venrock Healthcare Capital Par now holds 4,148,428 shares worth roughly $64.3 million.
Then, Venrock Healthcare Capital Par bought 14,950 shares, generating $173,868 in total proceeds. Upon buying the shares at $11.63, the 10% Owner now owns 4,059,634 shares.
Before that, Venrock Healthcare Capital Par bought 8,971 shares. Oruka Therapeutics Inc shares valued at $106,396 were divested by the 10% Owner at a price of $11.86 per share. As a result of the transaction, Venrock Healthcare Capital Par now holds 4,044,684 shares, worth roughly $62.69 million.
BTIG Research initiated its Oruka Therapeutics Inc [ORKA] rating to a Buy in a research note published on May 22, 2025; the price target was $44. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. Stifel began covering ORKA with “Buy” recommendation on October 11, 2024. H.C. Wainwright started covering the stock on October 07, 2024. It rated ORKA as “a Buy”.
Price Performance Review of ORKA
On Tuesday, Oruka Therapeutics Inc [NASDAQ:ORKA] saw its stock jump 8.39% to $15.5. Over the last five days, the stock has gained 12.89%. Oruka Therapeutics Inc shares have fallen nearly -18.86% since the year began. Nevertheless, the stocks have fallen -20.06% over the past one year.
How much short interest is there in Oruka Therapeutics Inc?
A steep rise in short interest was recorded in Oruka Therapeutics Inc stocks on 2025-07-15, growing by 1.02 million shares to a total of 3.82 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 2.8 million shares. There was a rise of 26.63%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 17, 2024 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $44 price target.
